🔥🚨OncoAlert Hot off the press. Just published JTO & JTO CRR Consensus #Recommendations from the International Association for the Study of Lung Cancer IASLC on: #Neoadjuvant & #Adjuvant Treatment for Early-Stage Resectable Non-small Cell #LungCancer 👇🏼 jto.org/article/S1556-…

On crossover - in 2 phase 3 nsclc trials (LAURA & KN189) where in-study drug was provided to pts w progression on control arm, rates were 81% & 57%. So my question to colleagues Timothée Olivier, MD Bishal Gyawali Alfredo Addeo MD What is an acceptable rate of crossover? 57% 81% or 100%? #lcsm

Vanessa Ospina Jonathan Spicer MD PhD IASLC AATS The Society of Thoracic Surgeons ESTS Canadian Association of Thoracic Surgeons Patrick Forde Grupo Español de Cáncer de Pulmón Denying the benefit of neoadjuvant treatment Ch-IO cannot be sustained, including N2 patients. That is what the studies say. You need to read them, treat patients and have experience and see it.

Durvalumab fails to improve outcomes in PD-L1+ lung cancer after surgery. More movement toward neoadjuvant? No doubt about benefit in neoadjuvant for IO at least in terms of EFS! #lcsm onclive.com/view/adjuvant-…

Interesting! BR.31, PEARLS and IMP10 tell us that adjuvant single agent immunotherapy benefit is not as strong as neoadjuvant chemo/IO. Does surgery or chemo remove the immune cells or stimulus responsive to the tumour?

Grand Cru Wexford on the way? rte.ie/news/ireland/2…

Welcome to the KRAS Kickers and our patients to hear updates from our researchers! ⁦KRASKickers⁩ ⁦Johns Hopkins Thoracic Oncology⁩ ⁦Sandra Misale⁩ ⁦Kristen A. Marrone, MD⁩

Delighted to see the growth of lung cancer clinical trials & accruals nationally 🇮🇪 Thanks to PI’s, study teams & patients, progress! CancerTrialsIreland 🌈 Beaumont RCSI Cancer Centre Trinity St James's Cancer Institute Cancer Trials Cork Irish Research Radiation Oncology Group University Of Limerick Cancer Trials Mater Ollscoil na Gaillimhe | University of Galway St Vincent's University Hospital (SVUH) Tallaght University Hospital (TUH) David O Reilly

We’re thrilled to share the Top 20 Voices in Lung Cancer on X, as chosen by their peers. 💫 These dedicated individuals are making a real impact in raising awareness, supporting patients, and driving research forward. Thank you for your tireless efforts and commitment. A

The JTO & JTO CRR has published the fully formatted manuscript for our resectable NSCLC consensus! Have a look and see what you think: jto.org/article/S1556-… Perhaps most notable from my perspective was the high level of agreement between the expert panel and the external

If somehow you missed the hurling today, sit back and watch this 7-min package. 82k in Croke Park. Incredible drama.

🫁 Join us for a three-part #CME series—get expert insight on the evolving treatment landscape for early-stage, resectable #NSCLC! Register for all events: Aug 23, Sep 3, & Sep 12. 👉 answersincme.com/92550007?Promo… #LungCancer #AnswersInCMELive #GetYourAnswersInCME #MedEd #LiveCME

Interesting ODAC, future perioperative trial designs should consider contribution of phases but AEGEAN (neoadjuvant chemo-durva followed by adj durva) looks like it will be approved. Would have been difficult not to do so post approval of KN671 with a very similar design. #lcsm

#LungSeries: w/ Patrick Forde we 🗣️ the SoC for early + locally adv NSCLC. How much benefit do we get from PostOp IO? Full discussion: - cancernetwork.com/treatment-algo… - oncbrothers.com/earlylung-2024 - Also on the “Oncology Brothers” podcast CancerNetwork® #lcsm #OncTwitter #MedTwitter

#WCLC24 abstract titles released! Don't miss the plenary Sunday September 8th at 8:30am PDT - I am particularly eager to see the ivonescimab vs pembro HARMONi-2 data from Dr. Caicun Zhou, Neocoast-2 from Dr. Tina Cascone, and the 77T vs CM816 analysis from Dr. Patrick Forde!

What's new and exciting data coming up at #WLCC24 . 1- Perioperative vs Neoadjuvant Nivo. Patient level data analysis. 2- Osimertinib with or without Savolitinib for met aberrant EGFR mutated 1st line NSCLC 3 - Aumolertinib maintenance after CTRT for stage 3 NSCLC ( polestar )

🔥#WCLC24 abstracts titles 🥇Presidential 1 ✅Chairs: Dr. Paul E. Van Schil, Karen Kelly 🎙️Patrick Forde 🎯Perioperative vs Neoadjuvant Nivolumab for Resectable NSCLC: Patient-Level Data Analysis of CheckMate 77T vs CheckMate 816 #LCSM IASLC OncoAlert cattendee.abstractsonline.com/meeting/20598

#WCLC24 is almost here! Make sure to catch these “can’t-miss” presentations during the Presidential Symposium. @oncoalert #lcsm

🫁 Join us for part 1 of a three-part series—learn more about ICI–based neoadjuvant or perioperative regimens for treatment of early-stage resectable #NSCLC. Register now for the Aug 23 event. bit.ly/46XyZnO w/Patrick Forde Stephen R Broderick MD MPHS #LungCancer #AnswersInCMELive

Surprising results, stereotactic radiation plus anti-PD1 for stage 1-2 NSCLC, addition of immunotherapy does not confer benefit #lcsm merck.com/news/merck-pro…